Analysts Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $34.50

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have been given a consensus recommendation of “Buy” by the six brokerages that are currently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have covered the stock in the last year is $34.50.

CAPR has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Maxim Group increased their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Oppenheimer reissued an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Piper Sandler began coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Cantor Fitzgerald boosted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th.

Capricor Therapeutics Price Performance

NASDAQ:CAPR opened at $13.76 on Thursday. The firm has a market capitalization of $625.67 million, a P/E ratio of -12.98 and a beta of 3.98. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40. The company’s 50-day simple moving average is $17.23 and its 200 day simple moving average is $10.70.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CAPR. SG Americas Securities LLC bought a new position in shares of Capricor Therapeutics during the 3rd quarter valued at approximately $133,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Capricor Therapeutics in the third quarter worth $161,000. Sassicaia Capital Advisers LLC bought a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at $192,000. BNP Paribas Financial Markets boosted its holdings in Capricor Therapeutics by 868.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after buying an additional 15,872 shares during the period. Finally, FMR LLC purchased a new stake in Capricor Therapeutics in the 3rd quarter worth $370,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.